172 related articles for article (PubMed ID: 23836086)
1. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.
Corstjens PL; Fidder HH; Wiesmeijer KC; de Dood CJ; Rispens T; Wolbink GJ; Hommes DW; Tanke HJ
Anal Bioanal Chem; 2013 Sep; 405(23):7367-75. PubMed ID: 23836086
[TBL] [Abstract][Full Text] [Related]
2. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
5. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
Steenholdt C; Ainsworth MA; Tovey M; Klausen TW; Thomsen OO; Brynskov J; Bendtzen K
Ther Drug Monit; 2013 Aug; 35(4):530-8. PubMed ID: 23765033
[TBL] [Abstract][Full Text] [Related]
6. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
7. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
9. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
11. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
[TBL] [Abstract][Full Text] [Related]
12. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.
Hernández-Breijo B; Chaparro M; Cano-Martínez D; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Gisbert JP; Guijarro LG;
Biochem Pharmacol; 2016 Dec; 122():33-41. PubMed ID: 27664854
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
[TBL] [Abstract][Full Text] [Related]
14. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
Wang SL; Ohrmund L; Hauenstein S; Salbato J; Reddy R; Monk P; Lockton S; Ling N; Singh S
J Immunol Methods; 2012 Aug; 382(1-2):177-88. PubMed ID: 22691619
[TBL] [Abstract][Full Text] [Related]
16. Significance of low level infliximab in the absence of anti-infliximab antibodies.
Ungar B; Anafy A; Yanai H; Ron Y; Yavzori M; Picard O; Fudim E; Loebstein R; Kopylov U; Chowers Y; Dotan I; Eliakim R; Ben-Horin S
World J Gastroenterol; 2015 Feb; 21(6):1907-14. PubMed ID: 25684959
[TBL] [Abstract][Full Text] [Related]
17. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
[TBL] [Abstract][Full Text] [Related]
18. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model.
Henriksen ML; Teisner A; Kjeldsen J; Kalliokoski O; Hau J; Hansen SW
In Vivo; 2016 09-10; 30(5):557-65. PubMed ID: 27566072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
